Project Grant R01CA292930
Award Date 8/5/25
Completion Date 7/31/29
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- The University of Texas Southwestern Medical Center received a $2,513,300 Project Grant award from the National Cancer Institute under the Cancer Centers Support Grants program (CFDA 93.397) to establish the UT Southwestern Liver Cancer SPORE (Specialized Program of Research Excellence). This 5-year grant aims to leverage innovative basic science discoveries to develop personalized medical interventions that can significantly reduce liver cancer mortality, with a focus on hepatocellular...
- The Project Grant award of $300,000.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) will support a study on the epidemiology of the gut-liver axis and its relationship to hepatocellular carcinoma (HCC) risk in a multiethnic liver cirrhosis cohort. The study aims to expand the existing Microbiome, Microbial Markers, and Liver Disease (M3LD) cohort by enrolling approximately 1,000 participants with liver cirrhosis, with a focus on...
- This Project Grant award of $671,384, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), aims to develop new and novel biomarkers for cholangiocarcinoma (CCA), a highly lethal form of liver cancer, based on glycan changes observed in CCA tissue and serum samples. The primary awardee, the Medical University of South Carolina, will lead the research effort to identify glycan biomarkers that can differentiate CCA from healthy or other diseased...
- This $580,238 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Regents of the University of Minnesota on January 10, 2025. The grant will fund a 5-year research project to investigate novel blood biomarkers that could predict the early development of hepatocellular carcinoma (liver cancer) in Hispanic individuals infected with the hepatitis B virus. The research aims to develop a non-visual screening approach...
- This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $518,219.00 to the University of Pittsburgh to conduct research aimed at deciphering the molecular mechanisms underlying the development of cholangiocarcinoma (CCA), a type of liver cancer. The project will investigate the intertwined roles of the nuclear receptors FXR and CAR in promoting the malignant transformation of hepatocytes into CCA, particularly in the context of...
- This federal Project Grant award of $165,883 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a research project led by Dr. Xinyuan (Cindy) Zhang at Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to improve early detection, causal inference, and lifestyle-based prevention for hepatocellular carcinoma (HCC). The key objectives of this 2-year research project are to: Use computational biology and system biology techniques to...
- The National Cancer Institute (NCI) awarded a $793,324 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors targeting the CYP8B1 enzyme as a novel approach to treat hepatocellular carcinoma (HCC), including metabolic dysfunction-associated HCC. The project aims to discover and validate CYP8B1 inhibitors that may provide a unique pharmacological therapy for HCC, which is the...
- This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...
- This Project Grant award of $306,739.00, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to improve treatment outcomes for patients with hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. The research focuses on identifying the most effective inhibitors of the enzyme ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) in HCC models. ENPP1 plays a key role in suppressing the immune response against HCC...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $195,180.00 to The Trustees of the University of Pennsylvania (UEI: GM1XX56LEP58) to conduct research on noninvasive assessment of isocitrate dehydrogenase (IDH) mutation status in intrahepatic cholangiocarcinoma (ICCA). This research aims to develop improved diagnostic capabilities for ICCA, which is the second most common primary liver cancer with a very poor prognosis. The...